EF Hutton analyst Elemer Piros reiterates Cybin (AMEX:CYBN) with a Buy and maintains $3 price target.
NexImmune Announces Research Collaboration With National Institute Of Neurological Disorders And Stroke Of The National Institutes Of Health
NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T
